Browse EyeWorld Weekly ophthalmology news on EyeWorld.org. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Topline results from trial for biologic eye drop for dry eye ➤ First patient dosed in Phase 3 trial evaluating oral non-opioid sedation ➤ First patient dosed in retinitis pigmentosa gene therapy trial ➤ Clinical program for IOP-lowering drug discontinued ➤ ASCRS news and events
➤ 52-week Phase 3 data published for cyclosporine, 0.1% ➤ First patient enrolled in Phase 3 trial assessing new treatment for MGD ➤ Geographic atrophy treatment trial advances to highest dose ➤ New dataset added to support various areas of research and development ➤ ASCRS news and events
➤ Twelve-month results for Phase 2 trial evaluating heat-therapy system for MGD ➤ Topline results from targeted photobiomodulation for treatment of progressive myopia ➤ Enrollment complete in Phase 3 trials to evaluate new wet AMD therapy ➤ ‘Low tech’ way to prioritize cataract surgery ➤ ASCRS news and events
➤ FDA grants 510(k) indication expansion for MIGS tool ➤ FDA approves biosimilar for aflibercept ➤ De Novo Marketing Authorization granted for home OCT device ➤ Consensus guidelines for suprachoroidal drug delivery ➤ ASCRS news and events
➤ Topline results for investigational first-in-class dry eye drop ➤ Dosing complete in second cohort of Stargardt disease gene therapy trial ➤ Enrollment complete for Phase 2 acute optic neuritis trial ➤ Enrollment complete for Phase 1/2a trial evaluating neovascular AMD therapy ➤ ASCRS news and events
➤ CRISPR gene-editing trial shows ‘exciting potential’ ➤ Study: laser vision correction clinics missing opportunities ➤ Broad-based protection observed with investigational geographic atrophy therapy ➤ FDA accepts IND for diabetic macular edema therapy ➤ Phase 2 trial for non-proliferative diabetic retinopathy therapy does not meet primary endpoint ➤ ASCRS news and events
➤ FDA clears fully autonomous, portable AI device for diabetic retinopathy screening ➤ Positive preliminary data for Phase 1/2 trial evaluating gene therapy treatment for X-linked retinoschisis ➤ Dosing in Phase 1/2 trial for allogenic cell therapy for corneal edema ➤ Dosing complete in trial assessing corneal edema therapy ➤ Phase 4 results for mydriasis product reported ➤ Collaboration seeks to commercialize Alzheimer’s detection through retinal imaging ➤ ASCRS news and events
➤ Topline results for investigational diabetic retinopathy therapy ➤ Dosing complete in second cohort for Phase 1/2 trial for geographic atrophy therapy ➤ Large data modules launched for dry eye disease and thyroid eye disease ➤ Study: Real-world outcomes of MIGS combined with cataract surgery vs. cataract surgery alone ➤ ASCRS news and events
➤ First patient enrolled in Phase 3 trial evaluating phentolamine ophthalmic solution ➤ FDA clears IND amendment for Phase 3 retinitis pigmentosa gene therapy study ➤ Successful pre-submission meetings held for bioengineered corneal implants ➤ Study: AI chatbots pass ophthalmology board certification questions ➤ ASCRS news and events
➤ Phase 3 results for new corticosteroid ➤ Positive topline results from Phase 3 trials investigating presbyopia drop ➤ Phase 2 data presented for IOP-lowering intracameral implant ➤ First patient dosed in retinitis pigmentosa gene therapy ➤ Survey shows burden of pterygium ➤ ASCRS news and events
Get the latest ophthalmology news delivered to your inbox every Friday.